Baseline characteristics of patients with VTE in RIETE, according to IT testing and its results
| . | Not tested . | Tested . | Positive IT (all IT types) . | Protein C deficiency only . | Protein S deficiency only . | Antithrombin deficiency only . | FVL only . | Prothrombin mutation only . | Combined IT . | Negative IT . |
|---|---|---|---|---|---|---|---|---|---|---|
| Patients, N | 82 729 | 21 089 | 8422 | 294 | 726 | 240 | 2248 | 1434 | 3480 | 12 667 |
| Demographics | ||||||||||
| Male sex | 40 214 (49%) | 11 021 (52%)∗ | 4592 (55%)∗ | 167 (57%)† | 327 (45%) | 147 (61%)∗ | 1271 (57%)∗ | 755 (53%)† | 1925 (55%)∗ | 6429 (51%)∗ |
| Age (mean y ± SD) | 68 ± 16 | 55 ± 18∗ | 53 ± 18∗ | 52 ± 17∗ | 52 ± 19∗ | 50 ± 19∗ | 50 ± 17∗ | 52 ± 17∗ | 57 ± 18∗ | 56 ± 18∗ |
| Body weight (mean kg ± SD) | 76 ± 16 | 78 ± 16∗ | 78 ± 17∗ | 77 ± 14 | 75 ± 16 | 79 ± 18† | 80 ± 17∗ | 79 ± 16∗ | 78 ± 17∗ | 78 ± 16∗ |
| Initial VTE presentation | ||||||||||
| PE | de | 10 164 (48%)∗ | 3747 (44%)∗ | 136 (46%)‡ | 316 (44%)∗ | 117 (49%) | 779 (35%)∗ | 685 (48%)∗ | 1714 (49%)∗ | 6417 (51%)∗ |
| Isolated lower-limb DVT | 32 057 (39%) | 9116 (43%)∗ | 3968 (47%)∗ | 135 (46%)‡ | 353 (49%)∗ | 102 (43%) | 1264 (56%)∗ | 642 (45%)∗ | 1472 (42%)∗ | 5148 (41%)∗ |
| Isolated upper-limb DVT | 3494 (4.2%) | 891 (4.2%) | 306 (3.6%)† | 9 (3.1%) | 20 (2.8%) | 7 (2.9%) | 91 (4.0%) | 38 (2.6%)† | 141 (4.1%) | 585 (4.6%)‡ |
| Splanchnic vein thrombosis | 386 (0.47%) | 223 (1.1%)∗ | 93 (1.1%)∗ | 4 (1.4%) | 9 (1.2%)† | 8 (3.3%)∗ | 6 (0.27%) | 23 (1.6%)∗ | 43 (1.2%)∗ | 130 (1.0%)∗ |
| Superficial vein thrombosis | 1777 (2.1%) | 441 (2.1%) | 199 (2.4%) | 5 (1.7%) | 20 (2.8%) | 5 (2.1%) | 84 (3.7%)∗ | 26 (1.8%) | 59 (1.7%) | 242 (1.9%) |
| Cerebral sinus vein thrombosis | 95 (0.11%) | 105 (0.50%)∗ | 47 (0.56%)∗ | 0 | 4 (0.55%)‡ | 1 (0.42%) | 7 (0.31%)‡ | 14 (0.98%)∗ | 21 (0.60%)∗ | 58 (0.46%)∗ |
| Other locations | 695 (0.84%) | 149 (0.71%) | 62 (0.74%) | 5 (1.7%) | 4 (0.55%) | 0 | 17 (0.76%) | 6 (0.42%) | 30 (0.86%) | 87 (0.69%) |
| Risk factors for VTE | ||||||||||
| Recent surgery | 9018 (11%) | 2075 (9.8%)∗ | 761 (9.0%)∗ | 26 (8.8%) | 76 (10%) | 20 (8.3%) | 164 (7.3%)∗ | 155 (11%) | 320 (9.2%)† | 1314 (10%) |
| Immobilization ≥4 days | 19 199 (23%) | 3762 (18%)∗ | 1313 (16%)∗ | 45 (15%)† | 127 (17%)∗ | 30 (13%)∗ | 297 (13%)∗ | 229 (16%)∗ | 585 (17%)∗ | 2449 (19%)∗ |
| Active cancer | 17 124 (21%) | 1595 (7.6%)∗ | 619 (7.3%)∗ | 14 (4.8%)∗ | 42 (5.8%)∗ | 12 (5.0%)∗ | 106 (4.7%)∗ | 88 (6.1%)∗ | 357 (10%)∗ | 976 (7.7%)∗ |
| Estrogen use | 3466 (4.2%) | 2365 (11%)∗ | 917 (11%)∗ | 20 (6.8%)‡ | 79 (11%)∗ | 16 (6.7%) | 286 (13%)∗ | 200 (14%)∗ | 316 (9.1%)∗ | 1448 (11%)∗ |
| Pregnancy or postpartum | 676 (0.8%) | 608 (2.9%)∗ | 295 (3.5%)∗ | 11 (3.7%)∗ | 43 (5.9%)∗ | 15 (6.3%)∗ | 75 (3.3%)∗ | 58 (4.0%)∗ | 93 (2.7%)∗ | 313 (2.5%)∗ |
| None of the above (unprovoked) | 40 190 (49%) | 11 945 (57%)∗ | 4986 (59%)∗ | 186 (63%)∗ | 404 (56%)∗ | 156 (65%)∗ | 1426 (63%)∗ | 801 (56%)∗ | 2013 (58%)∗ | 6959 (55%)∗ |
| Prior VTE | 11 300 (14%) | 3769 (18%)∗ | 1976 (23%)∗ | 96 (33%)∗ | 175 (24%)∗ | 81 (34%)∗ | 580 (26%)∗ | 292 (20%)∗ | 752 (22%)∗ | 1793 (14%) |
| . | Not tested . | Tested . | Positive IT (all IT types) . | Protein C deficiency only . | Protein S deficiency only . | Antithrombin deficiency only . | FVL only . | Prothrombin mutation only . | Combined IT . | Negative IT . |
|---|---|---|---|---|---|---|---|---|---|---|
| Patients, N | 82 729 | 21 089 | 8422 | 294 | 726 | 240 | 2248 | 1434 | 3480 | 12 667 |
| Demographics | ||||||||||
| Male sex | 40 214 (49%) | 11 021 (52%)∗ | 4592 (55%)∗ | 167 (57%)† | 327 (45%) | 147 (61%)∗ | 1271 (57%)∗ | 755 (53%)† | 1925 (55%)∗ | 6429 (51%)∗ |
| Age (mean y ± SD) | 68 ± 16 | 55 ± 18∗ | 53 ± 18∗ | 52 ± 17∗ | 52 ± 19∗ | 50 ± 19∗ | 50 ± 17∗ | 52 ± 17∗ | 57 ± 18∗ | 56 ± 18∗ |
| Body weight (mean kg ± SD) | 76 ± 16 | 78 ± 16∗ | 78 ± 17∗ | 77 ± 14 | 75 ± 16 | 79 ± 18† | 80 ± 17∗ | 79 ± 16∗ | 78 ± 17∗ | 78 ± 16∗ |
| Initial VTE presentation | ||||||||||
| PE | de | 10 164 (48%)∗ | 3747 (44%)∗ | 136 (46%)‡ | 316 (44%)∗ | 117 (49%) | 779 (35%)∗ | 685 (48%)∗ | 1714 (49%)∗ | 6417 (51%)∗ |
| Isolated lower-limb DVT | 32 057 (39%) | 9116 (43%)∗ | 3968 (47%)∗ | 135 (46%)‡ | 353 (49%)∗ | 102 (43%) | 1264 (56%)∗ | 642 (45%)∗ | 1472 (42%)∗ | 5148 (41%)∗ |
| Isolated upper-limb DVT | 3494 (4.2%) | 891 (4.2%) | 306 (3.6%)† | 9 (3.1%) | 20 (2.8%) | 7 (2.9%) | 91 (4.0%) | 38 (2.6%)† | 141 (4.1%) | 585 (4.6%)‡ |
| Splanchnic vein thrombosis | 386 (0.47%) | 223 (1.1%)∗ | 93 (1.1%)∗ | 4 (1.4%) | 9 (1.2%)† | 8 (3.3%)∗ | 6 (0.27%) | 23 (1.6%)∗ | 43 (1.2%)∗ | 130 (1.0%)∗ |
| Superficial vein thrombosis | 1777 (2.1%) | 441 (2.1%) | 199 (2.4%) | 5 (1.7%) | 20 (2.8%) | 5 (2.1%) | 84 (3.7%)∗ | 26 (1.8%) | 59 (1.7%) | 242 (1.9%) |
| Cerebral sinus vein thrombosis | 95 (0.11%) | 105 (0.50%)∗ | 47 (0.56%)∗ | 0 | 4 (0.55%)‡ | 1 (0.42%) | 7 (0.31%)‡ | 14 (0.98%)∗ | 21 (0.60%)∗ | 58 (0.46%)∗ |
| Other locations | 695 (0.84%) | 149 (0.71%) | 62 (0.74%) | 5 (1.7%) | 4 (0.55%) | 0 | 17 (0.76%) | 6 (0.42%) | 30 (0.86%) | 87 (0.69%) |
| Risk factors for VTE | ||||||||||
| Recent surgery | 9018 (11%) | 2075 (9.8%)∗ | 761 (9.0%)∗ | 26 (8.8%) | 76 (10%) | 20 (8.3%) | 164 (7.3%)∗ | 155 (11%) | 320 (9.2%)† | 1314 (10%) |
| Immobilization ≥4 days | 19 199 (23%) | 3762 (18%)∗ | 1313 (16%)∗ | 45 (15%)† | 127 (17%)∗ | 30 (13%)∗ | 297 (13%)∗ | 229 (16%)∗ | 585 (17%)∗ | 2449 (19%)∗ |
| Active cancer | 17 124 (21%) | 1595 (7.6%)∗ | 619 (7.3%)∗ | 14 (4.8%)∗ | 42 (5.8%)∗ | 12 (5.0%)∗ | 106 (4.7%)∗ | 88 (6.1%)∗ | 357 (10%)∗ | 976 (7.7%)∗ |
| Estrogen use | 3466 (4.2%) | 2365 (11%)∗ | 917 (11%)∗ | 20 (6.8%)‡ | 79 (11%)∗ | 16 (6.7%) | 286 (13%)∗ | 200 (14%)∗ | 316 (9.1%)∗ | 1448 (11%)∗ |
| Pregnancy or postpartum | 676 (0.8%) | 608 (2.9%)∗ | 295 (3.5%)∗ | 11 (3.7%)∗ | 43 (5.9%)∗ | 15 (6.3%)∗ | 75 (3.3%)∗ | 58 (4.0%)∗ | 93 (2.7%)∗ | 313 (2.5%)∗ |
| None of the above (unprovoked) | 40 190 (49%) | 11 945 (57%)∗ | 4986 (59%)∗ | 186 (63%)∗ | 404 (56%)∗ | 156 (65%)∗ | 1426 (63%)∗ | 801 (56%)∗ | 2013 (58%)∗ | 6959 (55%)∗ |
| Prior VTE | 11 300 (14%) | 3769 (18%)∗ | 1976 (23%)∗ | 96 (33%)∗ | 175 (24%)∗ | 81 (34%)∗ | 580 (26%)∗ | 292 (20%)∗ | 752 (22%)∗ | 1793 (14%) |